BWS Financial Downgrades SciClone Pharmaceuticals (SCLN) to Hold; Valuation Call After Recent Run-Up
More News related to SCLN
- SciClone (SCLN) Announces Enrollment for Phase 2 SCV-07 Complete
- SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07
- SciClone Pharmaceuticals to Present at the Piper Jaffray Annual Healthcare Conference
- SciClone Pharmaceuticals Announces Presentations of SCV-07 Data at Upcoming Medical Meetings
- National Securities Initiates Coverage on SciClone Pharmaceuticals (SCLN) with a Buy
BWS Financial downgrades SciClone Pharmaceuticals (Nasdaq: SCLN) from Buy to Hold.
BWS analyst says, "SCLN shares have been ascending since the beginning of this year. We fear some of the momentum is the cause of the Company indicating that there was stocking of ZADAXIN, thymalfasin, occurring in the early parts of the second quarter. This is likely to lead to second quarter revenue showing a growth rate that is unsustainable. Assumption that SCLN would be able to maintain such a growth rate is misplaced and is a formula for the Company disappointing investors. Therefore, it is prudent to move to the sidelines given that SCLN shares have nearly quintupled from their lows at the beginning of the year."
To see more analyst ratings on SCLN Click Here.
SciClone Pharmaceuticals, Inc. (SciClone ) is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat life-threatening diseases.
Related Categories
DowngradesStocks Mentioned
+0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
